Biotechnology

Enzolytics, Inc. Receives Official Filing Receipt for Multiple Sclerosis Patent Application

January 19, 2021 9:30 AM

Third Tranche of $1.2 Million Financing Completed COLLEGE STATION, TX / ACCESSWIRE / January 19, 2021 / Enzolytics, Inc. (OTC PINK:ENZC)(the "Company") today, announced it has received the official filing receipt from the U.S. Patent Office confirming the filing of its patent application for "Nuclear Proteins Isolated from Mammalian Spinal Cord Immune Factor - Pharmaceutical Composition for Treatment" and has received the third tranche of the...

Read more

Viewpoint Molecular Targeting(TM) Awarded $5 Million in Phase II SBIR Grants from the National Institutes of Health - National Cancer Institute

January 19, 2021 9:00 AM

- $2 million Phase II SBIR grant awarded to advance image-guided alpha-particle therapy for metastatic melanoma and radioisotope production technologies - Second year of a $2 million Phase II SBIR funding to begin a Phase 1 clinical imaging trial of complementary Pb-203 and Ga-68 diagnostics for metastatic melanoma - $2 million Phase II Small Business Innovation Research (SBIR) grant awarded to fund development activities and advance...

Read more

FDA Lifts Partial Clinical Hold on PRS-343 Phase 1 Studies

January 19, 2021 8:00 AM

BOSTON, MA / ACCESSWIRE / January 19, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that the U.S. Food and Drug Administration (FDA) has lifted the previously announced partial clinical hold on the phase 1 studies of PRS-343. As previously...

Read more

Nascent Biotech Research Partner, Manhattan BioSolutions, to Present at the ACCESS CHINA Forum at the 2021 JPMorgan Healthcare Conference

January 19, 2021 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / January 19, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO). Nascent Biotech Research Partner, Manhattan BioSolutions (MABS), Inc. announced that it will be presenting at the "ACCESS CHINA Forum at JP Morgan Week 2021" which is being held online on January 4th to 30th, 2021. Dr. Boris Shor, Co-founder and CEO of MABS, will be hosting presentation on Wednesday, January 20, 2021 at 9:20PM, EST. Sean Carrick, CEO of Nascent...

Read more

MJ Biotech Wholly Owned Subsidiary, New England Biotech And Joint Venture Partner Genesis Botanical Research Secures CBD Extraction Facility Location

January 19, 2021 8:00 AM

CHEYENNE, WY / ACCESSWIRE / January 19, 2021 / MJ Biotech, Inc. (OTC PINK:MJTV), is pleased to announce that it's partner Genesis Botanical Research, has secured the location for the first of their CBD extraction facilities. The facility, once constructed, will be owned by MJTV's wholly owned subsidiary New England Biotech, Inc. This first CBD extraction facility will be located in Sagadahoc County in the Mid-Coast-Central Maine area. The...

Read more

Mosaic ImmunoEngineering Inc. Announces Upgrade to OTCQB Venture Market and Upcoming Presentation at the B. Riley Oncology Investor Conference

January 19, 2021 8:00 AM

NOVATO, CA / ACCESSWIRE / January 19, 2021 / Mosaic ImmunoEngineering Inc., (the "Company" or "Mosaic") (OTC PINK:CPMV), a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases, announced today that it will begin trading on the OTCQB® Venture Market as of today, January 19, 2021. The Company also announced today that Steven King,...

Read more

Havn Life to Support Canadian Counterpart of Veterans' Organization, Heroic Hearts

January 18, 2021 8:00 AM

Havn Life to grow its partnership with the US-based veterans' organization by funding and supporting the launch of its Canadian counterpart. VANCOUVER, BC / ACCESSWIRE / January 18, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "Havn Life") a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce that it...

Read more

Lexaria Appoints New Board Member

January 15, 2021 3:35 PM

KELOWNA, BC / ACCESSWIRE / January 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors. Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions...

Read more

Lexaria Bioscience Corp. Announces Closing of $11 Million Public Offering with Full Exercise of Underwriter Option to Purchase Additional Shares and Warrants

January 15, 2021 6:30 AM

KELOWNA, BC / ACCESSWIRE / January 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company") today announced the closing of its previously announced underwritten public offering (the "Offering") of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise...

Read more

Wuhan General Group Closes Acquisition of Tsime Pharmaceuticals (PTY) Limited

January 14, 2021 9:00 AM

CAPE TOWN, SA / ACCESSWIRE / January 14, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce effective today, it has executed and closed the Acquisition (the "Transaction") of Tsime Pharmaceuticals (Pty) Ltd ("Tsime"). Tsime will become a subsidiary of MJ Medtech Inc. The Tsime license...

Read more

MJ Biotech Wholly Owned Subsidiary, New England Biotech Enters into HEMP/CBD Extraction Operating Agreement with Genesis Botanical Research

January 14, 2021 8:55 AM

CHEYENNE, WY / ACCESSWIRE / January 14, 2021 / MJ Biotech, Inc. (OTC PINK:MJTV), a company in CBD Extraction Business, today announced its wholly-owned subsidiary New England Biotech Inc. (NEBI) has entered into a Management/Operating agreement with Genesis Botanical Research (GBR). GBR is a company incorporated in the State of Maine where the First extraction facility will be located. The principals of GBR have been in the farming industry...

Read more

Xenetic Biosciences, Inc. to Present at NobleCon17

January 14, 2021 8:00 AM

FRAMINGHAM, MA / ACCESSWIRE / January 14, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present at NobleCon17 - Noble Capital Markets' Seventeenth Annual Investor Conference on...

Read more

Helix Biopharma Corp. Responds to Market Activity

January 13, 2021 3:55 PM

RICHMOND HILL, ON / ACCESSWIRE / January 13, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, wishes to confirm that it is not aware of any material, undisclosed information related to the Company that would account for the recent increase in the market price and level...

Read more

Ron Kilgarlin - Discusses a Broad Array of Home Drug Testing Products Offered by American Screening LLC

January 13, 2021 1:30 PM

SHREVEPORT, LA / ACCESSWIRE / January 13, 2021 / The initial mission of American Screening LLC was to provide high-quality drug and alcohol screening products. In time, the company has grown into a main domestic and international manufacturer and distributor of diagnostic tests and essential medical supplies. The business received an ISO13485 contract, which helped it to expand its goal of supporting the fight against drug addiction and mental...

Read more

OMNICANNA Announces Brand and Name Change to Thermic Sciences International (TSi) in Light of its Back-to-Back Groundbreaking Acquisitions of Thermic Coating Systems Ltd., and Cannabis Science Inc. (CSi) in Transition it Extends the (CSi First Rights) to February 14, 2021

January 13, 2021 9:00 AM

NASHVILLE, TN / ACCESSWIRE / January 13, 2021 / Omnicanna Health Solutions, Inc. aka ENDOCAN CORP. (WKN:A1W61J)(ISIN:US29271J1097)(OTC PINK:ENDO), announces brand and name change to Thermic Sciences International (TSi) in light of its back-to-back groundbreaking acquisitions of Thermic Coating Systems Ltd., and Cannabis Science Inc. (CSi) in Transition it Extends the (CSi First Rights) to February 14, 2021 (former CBIS Cannabis Science WKN:...

Read more

Protera Strengthens Board with Appointment of Dr. Oswaldo da Costa e Silva as Non-Executive Director

January 13, 2021 2:00 AM

SANTIAGO, CHILE and PARIS, FRANCE / ACCESSWIRE / January 13, 2021 / Protera, an AI-driven startup designing and developing new proteins to enable a wide range of natural and sustainable solutions, announced today it has appointed Dr. Oswaldo da Costa e Silva as Non-Executive Director to its Board. Dr. da Costa e Silva has over 20 years' experience working with and advising global agricultural biotech, life sciences and pharma corporations, as...

Read more

Hancock Jaffe Concludes Successful VenoValve Pre-IDE Meeting with FDA

January 12, 2021 8:30 AM

Company to Move Forward with Application for VenoValve U.S. Pivotal Trial IRVINE, CA / ACCESSWIRE / January 12, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has successfully concluded its VenoValve Pre-IDE meeting with the U.S. Food and Drug Administration ("FDA"). Topics presented at the meeting included the background and clinical...

Read more

Lexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering

January 12, 2021 7:00 AM

KELOWNA, BC / ACCESSWIRE / January 12, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company") today announced that its common stock and warrants will begin trading on the Nasdaq Capital Market on January 12, 2021, under the symbols "LEXX" and "LEXXW," respectively. Lexaria also announced the pricing of an underwritten public offering (the "Offering") of 1,828,571 units, each unit consisting of one share of common...

Read more

ZIVO Bioscience Successfully Confirms Poultry Growth Promotion and Feed Conversion Ratio Improvements in Typical Production Environments

January 11, 2021 2:50 PM

KEEGO HARBOR, MI / ACCESSWIRE / January 11, 2021 / ZIVO Bioscience, Inc. (OTCQB:ZIVO) a biotech/agtech R&D company engaged in the development and commercialization of therapeutic/additive product candidates originally derived from proprietary algal cultures, announces today that in its recent analysis of two poultry studies performed at separate research facilities, ZIVO product candidates provided statistically significant feed conversion...

Read more

Edesa Biotech expande estudio clínico para COVID-19 en Colombia

January 11, 2021 9:00 AM

TORONTO, ON / ACCESSWIRE / 11 de enero de 2021 / Edesa Biotech, Inc., compañía biofarmacéutica de etapa clínica recibió la aprobación del Ministerio de Salud y Protección Social a través del INVIMA en Colombia para ampliar el ensayo clínico de EB05, el fármaco en investigación, en pacientes hospitalizados con COVID-19. El estudio fue aprobado previamente en los EE. UU. y Canadá, donde se avanza la inscripción de pacientes. La compañía informó...

Read more